AstraZeneca stock dives 9% after heart drug trial misses target
Shares of AstraZeneca fell as much as 9% after a late-stage clinical trial for a heart disease drug…
Ionis gets approval for preventing attacks in rare and genetic HAE
In Ionis Pharmaceuticals Inc.’s second U.S. FDA approval in under a year, the agency approved Dawnzera (donidalorsen) as…